The AXL inhibitor (AXLi) BGB324 increases the sensitivity of A375 cells to the BRAF inhibitor (BRAFi) vemurafenib by stimulating ferroptosis and inhibiting autophagy, suggesting that a combination of AXLi with standard therapy is a promising approach to boost therapeutic outcomes in metastatic MM (Nyakas et al., 2022). This evidence concerns the gene AXL and Miyoshi myopathy.